Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

• Status: Completed
• Trial end date: 2015-01-13

Summary

To compare disease-free survival (DFS), overall survival (s), and toxicity of high-isk primary breast cancer patients with negative axillary lymph nodes or with one to three positive nodes treated with adjuvant high-dose chemotherapy with doxorubicin plus cyclophosphamide (AC), versus high-dose sequential chemotherapy with doxorubicin followed by cyclophosphamide (A-->C).

• Phase: Phase 3

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center; National Cancer Institute (NCI)
• Collaborator: Cancer and Leukemia Group B
• Treatments: Ciprofloxacin; Cyclophosphamide; Doxorubicin; Liposomal doxorubicin; Tamoxifen